BAX
USDBaxter International Inc. Common Stock
실시간 가격
가격 차트
핵심 지표
시장 지표
시가
$18.180
고가
$18.320
저가
$17.740
거래량
11.33M
기업 기본 정보
시가총액
9.2B
산업
Medical Instruments & Supplies
국가
United States
거래 통계
평균 거래량
6.80M
거래소
NYQ
통화
USD
52주 범위
관련 뉴스
BAX Investors Have Opportunity to Lead Baxter International Inc. Securities Fraud Lawsuit
Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Baxter International Inc. (NYSE: BAX) between February...
Baxter International, Inc. (BAX) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
The Law Offices of Frank R. Cruz announces that investors with losses related to Baxter International, Inc. ("Baxter" or the "Company") (NYSE: BAX)...
BAX INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Baxter International
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $10,000 In Baxter To Contact Him Directly To Discuss Their Options If you suffered losses
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Baxter International
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Baxter International Inc. ("Baxter" or the...
Baxter International, Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before December 15, 2025 to Discuss Your Rights - BAX
The Gross Law Firm issues the following notice to shareholders of Baxter International, Inc. (NYSE: BAX). Shareholders who purchased shares of BAX...
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Baxter International Inc. with Losses of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Baxter International Inc....
Citigroup Maintains Neutral on Baxter Intl, Lowers Price Target to $21
Citigroup analyst Joanne Wuensch maintains Baxter Intl with a Neutral and lowers the price target from $26 to $21.
